Physician profile
Shashideep Singhal
NPI 1891943098
$6,013.82
in general payments reported to CMS, 2019-2025
26 companies · $481 in 2025
The $481 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $429 · 2021: $903 · 2022: $1,226 · 2023: $817 · 2024: $798 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,253.99 | 2019-2025 | Linzess, Creon, Viberzi |
| E.R. Squibb & Sons, L.L.C. | $842.54 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $597.11 | 2019-2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $341.62 | 2019-2025 | Xifaxan, Plenvu |
| Intercept Pharmaceuticals, INC. | $218.66 | 2019-2024 | Ocaliva |
| Endogastric Solutions, INC | $188.16 | 2019-2024 | Esophyx |
| Takeda Pharmaceuticals U.S.A., INC. | $183.53 | 2019-2025 | Gattex, Entyvio |
| Madrigal Pharmaceuticals | $159.77 | 2024 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $139.46 | 2021-2023 | |
| Qol Medical, LLC | $120.04 | 2019-2022 | |
| Celgene Corporation | $111.82 | 2021-2024 | Zeposia |
| Concordia Pharmaceuticals INC. | $107.34 | 2019 | |
| Ardelyx, INC. | $98.46 | 2022-2025 | Ibsrela |
| Vivus LLC | $95.58 | 2021-2025 | Pancreaze |
| Janssen Biotech, INC. | $89.13 | 2021-2025 | Tremfya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $84.78 | 2020-2022 | |
| Pfizer INC. | $76.19 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $58.68 | 2024-2025 | Voquezna |
| Fujifilm Healthcare Americas Corporation | $46.57 | 2022 | |
| Braintree Laboratories, INC. | $45.73 | 2021-2023 | Suflave, Sutab |
| Evoke Pharma, INC. | $41.44 | 2022-2023 | Gimoti |
| Aimmune Therapeutics, INC. | $34.86 | 2025 | Zenpep |
| Alfasigma USA, INC. | $34.59 | 2020 | |
| Genzyme Corporation | $17.62 | 2022 | |
| Allergan, INC. | $13.24 | 2020 | |
| Ferring Pharmaceuticals INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashideep Singhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.